CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 25 enrolled
Drug / intervention
Imprimis Dropless +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02819908
NCT02819908Phase 4Completed
CompareCT.gov

Dropless™ vs. Less Drops™ Pharmaceutical Regimens After Cataract Surgery

Eye Center of North Florida·interventional·Posted Jun 30, 2016·Updated Mar 9, 2020

In Brief

A Phase 4 clinical trial evaluating Imprimis Dropless and Imprimis Less Drops for Intraocular Lens Associated Postoperative Inflammation. Completed, enrolled 25 participants across 1 site.

Detailed Summary

To compare the relative effectiveness of the Imprimis Dropless™ (TriMoxiVanc) intraocular solution with the Less Drops™ topical formulation of PredMoxiKeterolac (given for the first week post op) followed by PredKeterolac (given for weeks 2 to 4 after surgery). The hypothesis is that the "dropless" regimen will be non-inferior to the "less drops" regimen in terms of post-operative IOP changes, post-operative healing, and visual quality.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsIntraocular Lens Associated Postoperative Inflammation
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
20162017201820192020202120222023202420252026
First PostedJun 30, 2016
Enrollment StartSep 1, 2015
Primary CompletionApr 1, 2016
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 10.0 years ago

Interventions

Imprimis Droplessdrug

Tri-Moxi-Vanc transzonular intravitreal injection

Imprimis Less Dropsdrug

Pred-Moxi-Ketorolac and Pred-Ketorolac topical instillation qd postoperatively